Novo Nordisk Obesity Drug Disappoints Investors
- CHICAGO-Novo Nordisk's experimental obesity treatment, CagriSema, is showing efficacy and safety results comparable to Eli lilly's zepbound, according to recent late-stage trial data.This suggests CagriSema may not be...
- Previous reports from Novo Nordisk indicated that participants in a 68-week Phase 3 trial experienced a 20% weight loss while on cagrisema.This mirrors the weight loss levels observed...
- While Novo Nordisk intends to conduct a longer study of CagriSema to determine if patients can achieve further weight reduction, results released Sunday revealed that the rate of...
Novo Nordisk‘s CagriSema, a potential obesity weight loss drug, is facing headwinds, and initial trial data could disappoint investors. Recent late-stage results reveal efficacy similar too Zepbound. News Directory 3 can confirm that CagriSema’s weight loss plateaued after 68 weeks, raising questions about its long-term effectiveness.The drug’s performance has sparked concerns. The company plans further studies to understand if patients can achieve continued weight reduction. The current data implies that the anticipated groundbreaking impact may be limited. The market responded, and investors are looking for a breakthrough treatment in the field. Discover what’s next …
cagrisema Obesity Drug: Weight Loss Plateau Concerns Emerge
Updated June 22, 2025
CHICAGO-Novo Nordisk’s experimental obesity treatment, CagriSema, is showing efficacy and safety results comparable to Eli lilly’s zepbound, according to recent late-stage trial data.This suggests CagriSema may not be the groundbreaking treatment some investors anticipated for obesity weight loss drug.
Previous reports from Novo Nordisk indicated that participants in a 68-week Phase 3 trial experienced a 20% weight loss while on cagrisema.This mirrors the weight loss levels observed in studies of Zepbound.
While Novo Nordisk intends to conduct a longer study of CagriSema to determine if patients can achieve further weight reduction, results released Sunday revealed that the rate of obesity weight loss began to level off after 68 weeks. This raises questions about the potential for continued weight loss with the drug.
What’s next
The planned extended study aims to clarify whether CagriSema can facilitate continued weight loss beyond the initial 68 weeks, addressing concerns about the observed plateau effect.